(4S,6S,7Z,9S,10S)-4,6,9-Trihydroxy-10-nonyl-1-oxa-7-cyclodecene-2-one

Details

Top
Internal ID 42c616e5-b1ac-45d0-a500-1706fdcd2e44
Taxonomy Organoheterocyclic compounds > Oxocins
IUPAC Name (2S,3S,4Z,6S,8S)-3,6,8-trihydroxy-2-nonyl-2,3,6,7,8,9-hexahydrooxecin-10-one
SMILES (Canonical) CCCCCCCCCC1C(C=CC(CC(CC(=O)O1)O)O)O
SMILES (Isomeric) CCCCCCCCC[C@H]1[C@H](/C=C\[C@H](C[C@@H](CC(=O)O1)O)O)O
InChI InChI=1S/C18H32O5/c1-2-3-4-5-6-7-8-9-17-16(21)11-10-14(19)12-15(20)13-18(22)23-17/h10-11,14-17,19-21H,2-9,12-13H2,1H3/b11-10-/t14-,15+,16+,17+/m1/s1
InChI Key HFGOXJHLMBNOHC-YCCSFSNZSA-N
Popularity 0 references in papers

Physical and Chemical Properties

Top
Molecular Formula C18H32O5
Molecular Weight 328.40 g/mol
Exact Mass 328.22497412 g/mol
Topological Polar Surface Area (TPSA) 87.00 Ų
XlogP 3.30
Atomic LogP (AlogP) 2.47
H-Bond Acceptor 5
H-Bond Donor 3
Rotatable Bonds 8

Synonyms

Top
There are no found synonyms.

2D Structure

Top
2D Structure of (4S,6S,7Z,9S,10S)-4,6,9-Trihydroxy-10-nonyl-1-oxa-7-cyclodecene-2-one

3D Structure

Top

ADMET Properties (via admetSAR 2)

Top
Target Value Probability (raw) Probability (%)
Human Intestinal Absorption + 0.9067 90.67%
Caco-2 - 0.6770 67.70%
Blood Brain Barrier - 0.6500 65.00%
Human oral bioavailability - 0.6857 68.57%
Subcellular localzation Mitochondria 0.5454 54.54%
OATP2B1 inhibitior - 0.8566 85.66%
OATP1B1 inhibitior + 0.8918 89.18%
OATP1B3 inhibitior + 0.9338 93.38%
MATE1 inhibitior - 1.0000 100.00%
OCT2 inhibitior - 0.9500 95.00%
BSEP inhibitior - 0.7560 75.60%
P-glycoprotein inhibitior - 0.8633 86.33%
P-glycoprotein substrate - 0.7781 77.81%
CYP3A4 substrate - 0.5309 53.09%
CYP2C9 substrate - 1.0000 100.00%
CYP2D6 substrate - 0.8541 85.41%
CYP3A4 inhibition - 0.5151 51.51%
CYP2C9 inhibition - 0.9272 92.72%
CYP2C19 inhibition - 0.6073 60.73%
CYP2D6 inhibition - 0.9341 93.41%
CYP1A2 inhibition - 0.7395 73.95%
CYP2C8 inhibition - 0.8734 87.34%
CYP inhibitory promiscuity - 0.9203 92.03%
UGT catelyzed + 0.6000 60.00%
Carcinogenicity (binary) - 0.9600 96.00%
Carcinogenicity (trinary) Non-required 0.7124 71.24%
Eye corrosion - 0.9847 98.47%
Eye irritation - 0.8421 84.21%
Skin irritation + 0.5414 54.14%
Skin corrosion - 0.8820 88.20%
Ames mutagenesis - 0.7500 75.00%
Human Ether-a-go-go-Related Gene inhibition - 0.4372 43.72%
Micronuclear - 0.9200 92.00%
Hepatotoxicity + 0.5218 52.18%
skin sensitisation - 0.7805 78.05%
Respiratory toxicity + 0.5556 55.56%
Reproductive toxicity + 0.6034 60.34%
Mitochondrial toxicity + 0.7750 77.50%
Nephrotoxicity + 0.5210 52.10%
Acute Oral Toxicity (c) III 0.5149 51.49%
Estrogen receptor binding + 0.7585 75.85%
Androgen receptor binding - 0.5588 55.88%
Thyroid receptor binding + 0.6412 64.12%
Glucocorticoid receptor binding + 0.6853 68.53%
Aromatase binding - 0.7299 72.99%
PPAR gamma + 0.5367 53.67%
Honey bee toxicity - 0.9570 95.70%
Biodegradation - 0.6500 65.00%
Crustacea aquatic toxicity + 0.7934 79.34%
Fish aquatic toxicity + 0.9371 93.71%

Targets

Top

Proven Targets:

CHEMBL ID UniProt ID Name Min activity Assay type Source
No proven targets yet!

Predicted Targets (via Super-PRED):

CHEMBL ID UniProt ID Name Probability Model accuracy
CHEMBL3251 P19838 Nuclear factor NF-kappa-B p105 subunit 94.78% 96.09%
CHEMBL2581 P07339 Cathepsin D 94.38% 98.95%
CHEMBL253 P34972 Cannabinoid CB2 receptor 89.48% 97.25%
CHEMBL3108638 O15164 Transcription intermediary factor 1-alpha 89.22% 95.56%
CHEMBL3060 Q9Y345 Glycine transporter 2 88.86% 99.17%
CHEMBL299 P17252 Protein kinase C alpha 88.55% 98.03%
CHEMBL3137262 O60341 LSD1/CoREST complex 88.06% 97.09%
CHEMBL5619 P27695 DNA-(apurinic or apyrimidinic site) lyase 87.58% 91.11%
CHEMBL2996 Q05655 Protein kinase C delta 86.64% 97.79%
CHEMBL4769 O95749 Geranylgeranyl pyrophosphate synthetase 84.83% 92.08%
CHEMBL4793 Q86TI2 Dipeptidyl peptidase IX 82.59% 96.95%
CHEMBL2274 Q9H228 Sphingosine 1-phosphate receptor Edg-8 81.78% 100.00%

Cross-Links

Top
PubChem 44632077
NPASS NPC258037
LOTUS LTS0227071
wikiData Q105027300